Cover Image

Nirmatrelvir/ritonavir for patients with SARS-CoV-2 infection and impaired kidney function during the Omicron surge

Background: Nirmatrelvir/ritonavir has demonstrated effectiveness in high-risk patients with coronavirus disease 2019 (COVID-19). However, investigations on the efficacy and safety of nirmatrelvir/ritonavir in patients with kidney dysfunction are limited.Methods: Data were collected from the patient...

Full description

Saved in:

Bibliographic Details
Main Authors:	Jiayi Yan (Author), Hong Cai (Author), Jieying Wang (Author), Mingli Zhu (Author), Ping Li (Author), Peiying Li (Author), Bin Wu (Author), Xiajing Che (Author), Leyi Gu (Author), Shan Mou (Author)
Format:	Book
Published:	Frontiers Media S.A., 2023-03-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Nirmatrelvir/Ritonavir for hemodialysis patients with COVID-19
by: Jiayue Lu, et al.
Published: (2023)

Clinical outcomes of nirmatrelvir-ritonavir use in pregnant women during the Omicron wave of the coronavirus disease 2019 pandemic
by: Chih-Wei Lin, et al.
Published: (2023)

Viral rebound and safety of nirmatrelvir/ritonavir for lung-transplant recipients infected with SARS-CoV-2
by: Hui Li, et al.
Published: (2023)

Inpatient remdesivir versus nirmatrelvir-ritonavir in the progression of COVID-19
by: Dimple Patel, et al.
Published: (2023)

Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark?
by: Yuan-Pin Hung, et al.
Published: (2022)

Adverse Events Associated with Nirmatrelvir/Ritonavir: A Pharmacovigilance Analysis Based on FAERS
by: Meng Li, et al.
Published: (2022)

Economic Evaluation of Nirmatrelvir/Ritonavir Among Adults Against Hospitalization During the Omicron Dominated Period in Malaysia: A Real-World Evidence Perspective
by: Ee Vien Low, et al.
Published: (2024)

Dosing recommendation of nirmatrelvir/ritonavir using an integrated population pharmacokinetic analysis
by: Phylinda L. S. Chan, et al.
Published: (2023)

Is the Combination Nirmatrelvir Plus Ritonavir Effective for Treating or Preventing COVID-19?
by: article Editorial
Published: (2022)

Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19
by: Samuel Theodorus Sutanto, et al.
Published: (2022)

Nirmatrelvir-ritonavir treatment on SARS-CoV-2 viral dynamics in high altitude habitants
by: Aili Lu, et al.
Published: (2023)

The Development of an Oral Solution Containing Nirmatrelvir and Ritonavir and Assessment of Its Pharmacokinetics and Stability
by: Lili Wang, et al.
Published: (2024)

The omicron surge - Beginning of the pandemic's end?
by: Snigdha Goyal, et al.
Published: (2023)

Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life
by: Luca Cegolon, et al.
Published: (2023)

A retrospective analysis of factors associated with the length of hospital stay in COVID-19 patients treated with Nirmatrelvir / Ritonavir
by: Jiantao Zheng, et al.
Published: (2023)

Managing nirmatrelvir/ritonavir during COVID-19: pharmacists' experiences from the Perak state of Malaysia
by: Chee Tao Chang, et al.
Published: (2022)

Resistance to nirmatrelvir due to mutations in the Mpro in the subvariants of SARS-CoV-2 Omicron: Another concern?
by: Srijan Chatterjee, et al.
Published: (2023)

Case report and literature review: management of Paxlovid (nirmatrelvir/ritonavir)-induced acute tacrolimus toxicity in a patient with systemic lupus erythematosus
by: Chenxiao Jiang, et al.
Published: (2024)

Estudio de utilización de nirmatrelvir/ritonavir en tres centros de atención primaria durante 2022
by: José Miguel Sotoca-Momblona, et al.
Published: (2023)

Evaluation of the drug-drug interactions management system for appropriate use of nirmatrelvir/ritonavir: a retrospective observational study
by: Takeshi Tomida, et al.
Published: (2024)

Influence of ensitrelvir or nirmatrelvir/ritonavir on tacrolimus clearance in kidney transplant recipients: a single-center case series
by: Hanako Naganawa, et al.
Published: (2024)

Treatment of acute tacrolimus toxicity with phenytoin after Paxlovid (nirmatrelvir/ritonavir) administration in a kidney transplant recipient
by: Eun-Jeong Kwon, et al.
Published: (2022)

Evaluation of the efficacy and safety of nirmatrelvir/ritonavir co-administration inpatients with rheumatic disease infected with SARS-CoV-2: a real-world study
by: Xue Zhong, et al.
Published: (2023)

Real-world effectiveness and safety of nirmatrelvir-ritonavir (Paxlovid)-treated for COVID-19 patients with onset of more than 5 days: a retrospective cohort study
by: Ye Qiu, et al.
Published: (2024)

Modelling the end of a Zero-COVID strategy using nirmatrelvir/ritonavir, vaccination and NPIs in Wallis and FutunaResearch in context
by: Antoine Brault, et al.
Published: (2023)

Oral Molnupiravir and Nirmatrelvir/Ritonavir for the Treatment of COVID-19: A Literature Review with a Focus on Real-World Evidence
by: Ioannis Karniadakis, et al.
Published: (2023)

Case report: Supratherapeutic tacrolimus concentrations with nirmatrelvir/ritonavir in a lung transplant patient: a case report using Rifampin for reversal
by: Yu Xiong, et al.
Published: (2023)

MODERN DIRECTED ANTIVIRAL COVID-19 THERAPY: RESULTS OF MULTICENTER CLINICAL EFFECTIVENESS AND SAFETY STUDY OF FIXED NIRMATRELVIR+RITONAVIR COMBINATION
by: L. A. Balykova, et al.
Published: (2022)

SARS-CoV-2 in Malaysia: A surge of reinfection during the predominantly Omicron period
by: Su Lan Yang, et al.
Published: (2022)

Comparative analysis of the safety and effectiveness of Nirmatrelvir-Ritonavir and Azvudine in older patients with COVID-19: a retrospective study from a tertiary hospital in China
by: Nan Shang, et al.
Published: (2024)

Head-to-head comparison of azvudine and nirmatrelvir/ritonavir for the hospitalized patients with COVID-19: a real-world retrospective cohort study with propensity score matching
by: An-Hua Wei, et al.
Published: (2023)

Real-World Utilization of Molnupiravir during the COVID-19 Omicron Surge in Israel
by: Clara Weil, et al.
Published: (2023)

Insights from a community-based survey on factors influencing acceptance and uptake of Paxlovid (nirmatrelvir and ritonavir) as a COVID-19 antiviral medication in Singapore
by: Sheng En Alexius Matthias Soh, et al.
Published: (2024)

Case report: Application of nirmatrelvir/ritonavir to treat COVID-19 in a severe aplastic anemia child after allogeneic hematopoietic stem cell transplantation
by: Jinhua Huang, et al.
Published: (2022)

Case report: Paralytic ileus resulted from nirmatrelvir/ritonavir-tacrolimus drug-drug interaction in a systemic lupus erythematosus patient with COVID-19
by: Wei Zhang, et al.
Published: (2024)

A case report of a prolonged decrease in tacrolimus clearance due to co-administration of nirmatrelvir/ritonavir in a lung transplant recipient receiving itraconazole prophylaxis
by: Ayumi Tsuzawa, et al.
Published: (2023)

SGLT2i: Therapeutic options or contributing factors of contrast-induced acute kidney injury in the setting of non-diabetes?
by: Jiajia Wu, et al.
Published: (2023)

Review of clinical characteristics and mortality outcomes in patients on maintenance hemodialysis during the Omicron surge: a single center experience
by: Yiyang Xue, et al.
Published: (2024)

Thymoquinone's Antiviral Effects: It is Time to be Proven in the Covid-19 Pandemic Era and its Omicron Variant Surge
by: Maen Abdelrahim, et al.
Published: (2022)

Association of Molnupiravir and Nirmatrelvir-Ritonavir with preventable mortality, hospital admissions and related avoidable healthcare system cost among high-risk patients with mild to moderate COVID-19
by: Abraham Ka-Chung Wai, et al.
Published: (2023)